Medication · September 2026
A genuinely new painkiller arrived in 2025, and patients are asking about it. Here is what the evidence actually supports — and where it likely doesn't apply.
If you have read about a new non-opioid painkiller and wondered whether it could help you, here is a straight answer: the medication is real, it is genuinely new science, and it was probably not designed for the kind of pain that brings you to a pain clinic.
Suzetrigine, sold as Journavx, was approved by the FDA in January 2025. It is the first oral painkiller with a genuinely new mechanism in more than two decades, which is why it drew so much attention.
It works by blocking a sodium channel called Nav1.8, found on pain-sensing nerves outside the brain and spinal cord. That matters because opioids act centrally, in the brain, which is what produces sedation, respiratory depression, and the potential for dependence. A medication that works only at the peripheral nerve avoids that whole category of risk.
This is the part most news coverage glosses over. Suzetrigine is approved for moderate to severe acute pain in adults — the pain after surgery or an injury. Its safety and effectiveness in chronic pain, or for use beyond about two weeks, are still being studied.
Chronic pain and acute pain are different problems. Acute pain is a signal from damaged tissue that fades as the tissue heals. Chronic pain often continues after healing, involves changes in how the nervous system processes signals, and rarely responds to the same tools.
In early research the results have been mixed, and the pattern is informative. In small studies the medication helped people with painful diabetic neuropathy — but it was no better than placebo for sciatica, the radiating leg pain caused by an irritated spinal nerve.
That distinction matters here. A large share of the back pain we see involves exactly that mechanism.
Prescribing data tells an interesting story. An analysis of more than 3.6 million adults who received a new prescription for either suzetrigine or an opioid between February 2025 and April 2026 found that roughly a third of suzetrigine prescriptions were written for chronic pain, rather than the acute pain it was approved for. Patients receiving it also skewed older, with about 43% aged 65 or over.
Off-label prescribing is legal and sometimes appropriate — physicians do it thoughtfully all the time. But it means a medication is being used in a population where it has not been studied, and where the clinical trial results available so far suggest, at best, modest benefit.
If you are recovering from surgery or a recent injury, this is a reasonable thing to ask your surgeon about, particularly if you would prefer to avoid opioids.
If you have had back, neck, or nerve pain for months or years, it is worth knowing that this medication was not developed for your situation, and the early evidence in chronic pain is not strong. That is not a reason to dismiss it — it is a reason to be realistic, and to ask what the goal would be before starting it.
It is also worth checking cost. Coverage varies considerably between plans, and some patients have found it placed on a high formulary tier.
Our approach to medication has not changed because a new drug exists. The question is always the same: what type of pain is this, and what is the best-matched treatment for it?
Nerve pain, inflammatory pain, and muscle-driven pain each respond to different medications, and most of the medication problems we find are mismatches rather than failures of medicine. Sometimes the most useful change is reducing something that stopped helping, not adding something new.
If you have read about this medication and want to know whether it fits your situation, bring it up. We would rather have that conversation than have you wonder.
This article is general information about developments in pain medicine. It is not medical advice, not a recommendation for or against any product or treatment, and it does not describe services offered at CPMC unless stated. Whether any of this applies to you depends on your diagnosis and history — that is a conversation for your appointment.